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Abstract
Objective: Tuberculosis (TB) remains the leading cause of death among infectious diseases worldwide. It has been
suggested as an important risk factor of chronic obstructive pulmonary disease (COPD), which is also a major cause of
morbidity and mortality. This study investigated the impact of pulmonary TB and anti-TB treatment on the risk of
developing COPD.
Design, Setting, and Participants: This cohort study used the National Health Insurance Database of Taiwan, particularly
the Longitudinal Health Insurance Database 2005 to obtain 3,176 pulmonary TB cases and 15,880 control subjects matched
in age, sex, and timing of entering the database.
Main Outcome Measures: Hazard ratios of potential risk factors of COPD, especially pulmonary TB and anti-TB treatment.
Results: The mean age of pulmonary TB cases was 51.9619.2. The interval between the initial study date and
commencement of anti-TB treatment (delay in anti-TB treatment) was 75.8665.4 days. Independent risk factors for
developing COPD were age, male, low income, and history of pulmonary TB (hazard ratio 2.054 [1.768–2.387]), while
diabetes mellitus was protective. The impact of TB persisted for six years after TB diagnosis and was significant in women
and subjects aged .70 years. Among TB patients, delay in anti-TB treatment had a dose-response relationship with the risk
of developing COPD.
Conclusions: Some cases of COPD may be preventable by controlling the TB epidemic, early TB diagnosis, and prompt
initiation of appropriate anti-TB treatment. Follow-up care and early intervention for COPD may be necessary for treated TB
patients.
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Introduction
Chronic obstructive pulmonary disease (COPD), characterized
by chronic airway inflammation with progressive lung function
deterioration, is a major cause of morbidity, disability, and
mortality [1]. It is the fourth leading cause of death worldwide,
with a pooled prevalence of 6.4%, 1.8%, and 9.2% based on the
definition of chronic bronchitis, emphysema, and airflow obstruc-
tion, respectively [2,3]. Although tobacco smoking is recognized as
an important risk factor of COPD, indoor air pollution like
biomass fuel, occupational dusts, and exposure to certain gases,
history of pulmonary tuberculosis (TB), chronic asthma, poor
socio-economic status, and genetic factors are recognized as
potential factors contributing to the development of COPD [4].
The prevalence of COPD among non-smokers is reported to be
6.6% and an estimated 25–45% of COPD patients have never
smoked [4,5]. A nationwide survey in South Africa suggests that in
a TB endemic area, pulmonary TB may be the strongest risk
factor of COPD [6].
Tuberculosis poses a global public health threat and remains the
leading cause of death among infectious diseases, especially in
undeveloped and developing countries [7]. While TB can occur in
any organ or tissue, the respiratory system is the most common site
of active disease. Without treatment, TB has characteristic chronic
inflammation and has a mortality rate of 50% within five years [8].
Although standard anti-TB treatment is highly effective, with
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37978a rapid resolution of symptoms and low rate of relapse, non-
adherence remains a great obstacle to successful treatment [9].
After completing treatment for pulmonary TB, about two-thirds of
patients have pulmonary function abnormalities, with obstructive
defect being the main abnormality [10–13].
Theoretically, delay or non-adherence in anti-TB treatment
may increase the duration and severity of airway inflammation
and lung destruction, thus rendering the development of COPD.
However, the association between anti-TB treatment course and
COPD has never been elucidated. This cohort study was
conducted using the database of the National Health Insurance
(NHI) of Taiwan to investigate the influence of pulmonary TB and
delay and non-adherence of anti-TB treatment on the risk of
developing COPD.
Materials and Methods
The study has been approved by the institutional review board
(IRB) of National Taiwan University Hospital, Taipei, Taiwan. As
a retrospective study using an encrypted database, the IRB waved
the need for informed consent for this study.
Data Source and Case Selection
The NHI of Taiwan is a mandatory universal health insurance
program offering comprehensive medical care coverage to all
Taiwanese (Supporting Information S1). The Longitudinal Health
Insurance Database (LHID) 2005, a subset database of the NHI
program, contained the entire original claim data from 1996 to
2007 of 1,000,000 beneficiaries randomly sampled from the year
2005 Registry for Beneficiaries of the NHI program. From the
LHID 2005, pulmonary TB cases (TB group) and control subjects
(control group) matched in age, sex, and timing of entering the
database were selected (1:5 in case number).
Definition of Active Tuberculosis
Active pulmonary TB was defined by at least two ambulatory
visits or one in-patient record, with a compatible diagnosis plus at
least one prescription consisting of three or more than three anti-
TB drugs and prescriptions of at least two anti-TB drugs
simultaneously for $120 days during a period of 180 days
(Supporting Information S1). For patients with end-stage renal
disease, the prescriptions were adjusted as advised in the treatment
guidelines [14]. Patients with pulmonary TB onset prior to
January 1, 1999 were excluded to ensure an observation period of
three years to monitor active COPD treatment or diagnoses.
Patients with ,1 year of follow-up after pulmonary TB were also
excluded because remaining period of observation was insufficient
to confirm the subsequent development of COPD.
Because the health system delay in TB diagnosis had been
reported to vary from 3 to 6 months [15,16], the initial study date
in the TB group was defined as the initial date of anti-TB
treatment, and was moved forward if there were other respiratory
diagnoses or orders of acid-fast smear, mycobacterial culture,
bronchoscopy, pleural biopsy, or tuberculin skin test within 180
days prior to start of anti-TB treatment (Supporting Information
S1). The delay in anti-TB treatment was defined as the interval
between the initial study date and the date of the commencement
of anti-TB treatment. In the control group, the initial study date of
each subject was defined as the same day as the corresponding TB
case.
Definition of Chronic Obstructive Pulmonary Disease
The ambulatory care and in-patient discharge records were
analyzed to recognize COPD patients. COPD was defined by at
least two ambulatory or in-patient records with compatible
diagnoses with prescription of at least two COPD-specific
medications or one COPD-specific medication plus at least one
airway medication(s) during a period of 90 days (Supporting
Information S1). Patients with COPD onset prior to January 1,
1999 were excluded to ensure an observation period of three years
to monitor the occurrence of active TB. In order to confirm the
diagnosis of COPD, the total duration of active follow-up for
COPD had to be .1 year and the confirmed date of COPD was
therefore noted as 1 year later.
Data Collection
Underlying co-morbidities and income status were also identi-
fied from the LHID 2005 (Supporting Information S1). The end
study date was defined as the date COPD diagnosis was confirmed
in COPD patients, and the end of follow-up in those without
COPD. Subjects without COPD who canceled health insurance
before December 31, 2007 were censored from survival analyses at
the date of cancellation. The cumulative dosage of isoniazid,
rifampicin, ethambutol, and pyrazinamide during the intensive
phase (first two months) of anti-TB treatment was measured.
Adherence to anti-TB treatment was estimated by number of days
during the intensive phase covered by three or more anti-TB drugs
and non-adherence by the number of days during the intensive
phase covered by one or none of the anti-TB drugs.
Statistical Analysis
Intergroup difference was calculated using independent-samples
t test for continuous variables and chi square test or Fisher exact
test for categorical variables, as appropriate. The degree of
association between two variables was estimated by using Kendall
correlation test. Time-to-event curves were generated using the
Kaplan-Meier method and compared by log-rank test. Cox
proportional hazards regression analysis was performed to
evaluate the impact of age, gender, co-morbidities, income status,
active pulmonary TB, and treatment-associated variables on risk
of developing COPD (Supporting Information S1). The entry level
and stay level in stepwise variable selection procedure were set at
0.15. Only variables with a two-sided p,0.05 were kept in final
model. All analyses were performed using the SAS version 9.2
(SAS Institute Inc., Cary, NC, USA).
Since pulmonary function tests were not universally performed
and their results were not available, the onset of COPD might
precede its diagnosis by many years. Sensitivity analyses were
performed, whereby the impact of pulmonary TB in different age
groups and sub-populations with different follow-up durations
were evaluated. Because tobacco use was uncommon in female
Taiwanese (4.2%) [17], analysis was restricted to the sub-
population of females to explore the impact of confounding bias
by smoking.
Results
Among the 1,000,000 beneficiaries in LHID 2005, 995,549 had
sought medical help at least once from 1996 to 2007. Among
them, 52,684 and 5,073 subjects had COPD and pulmonary TB,
respectively. A total of 3,176 cases fulfilled the diagnostic criteria of
pulmonary TB and were selected as the TB group. Then 15,880
non-TB cases matched for age, gender, and timing of entering
LHID 2005 were selected as the control group (Fig. 1). Their
clinical characteristics assessed at the initial study date were
summarized in Table 1. The mean age of TB cases were
51.9619.2, with male predominance (male-to-female ratio, 1.9).
Pulmonary TB-Induced COPD
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were diabetes mellitus and malignancy.
Sixteen subjects (0.5%) in the TB group and 60 (0.4%) in the
control group cancelled health insurance during follow-up. The
interval between initial study date and commencement of anti-TB
treatment (delay in anti-TB treatment) was 75.8665.4 days. The
TB group had significantly higher risk of developing COPD than
the control group (7.6% vs. 3.9%, p,0.001 by chi square test). The
Figure 1. Case selection flow chart. The selection of pulmonary tuberculosis (TB) patients and age- and sex-matched control subjects from the
Longitudinal Health Insurance Database 2005.
doi:10.1371/journal.pone.0037978.g001
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group (2.3 vs. 2.5 years, p=0.050 by t test). Compared to non-TB
subjects, the TB subjects were more likely to have underlying co-
morbidities, including diabetes mellitus, malignancy, end-stage
renal disease, autoimmune disease, liver cirrhosis, and acquired
immuno-deficiency syndrome (AIDS).
Furthermore, more TB subjects had low income as compared to
the control subjects. Comparing to controls, TB patients had more
prescriptions of antitussives and COPD-specific medication after
the initial study date, whereas the frequency of prescriptions was
similar before the initial study date (Fig. 2). In addition, the
proportion of TB patients who had undergone spirometry was
higher before (3.2% vs. 2.4%, p=0.006 by chi square test) and
after (15.6% vs. 4.7%, p,0.001 by chi square test) the initial study
date (Fig. 2). The time-to-COPD curves of the two groups were
significantly different as calculated by log-rank test (Fig. 3).
Cox proportional hazards regression analysis, including all the
variables listed in Table 1 for the 3,176 pulmonary TB cases and
15,880 control subjects, revealed that pulmonary TB was a risk
factor for developing COPD (hazard ratio [HR] 2.054 [range,
1.768–2.387]) (Table 2). Age, male sex, and low income were risk
factors for developing COPD, whereas diabetes mellitus was
protective. Sensitivity analyses revealed that pulmonary TB
remained an independent risk factor for developing COPD in
cases of different follow-up durations after the initial study date,
ranging from .2t o.6 years (Table 3) (Supporting Information
S1). The TB HR (4.291 [range, 2.623–7.020]) for developing
COPD among patients aged ,40 years was higher than that
among of patients aged .40 year (Table 3). However, pulmonary
TB was an independent risk factor for developing COPD even
among subjects older than 70 years. In the sensitivity analysis that
included females only, pulmonary TB remained an independent
risk factor for developing COPD, while the magnitude of
association was higher than those of males or the overall
population (HR 2.473 [range, 1.782–3.433]) (Table 3). Diabetes
mellitus was not protective in the female sub-population.
The clinical characteristics assessed at the initial study date of
TB cases with or without developing COPD were shown in
Table 4. The mean age of TB patients who developed COPD was
62.5614.9 years, with male predominance (male-to-female ratio,
3.5). The most common underlying co-morbidity in TB cases
developing COPD was diabetes mellitus, followed by malignancy.
Among all TB cases, the median and mean delays in anti-TB
treatment were 66 and 75.8 days, respectively. Delay in anti-TB
treatment was #7, 8–90, and .90 days in 25.5%, 32.2%, 42.3%
of TB cases, respectively. The entire treatment course strictly
adhered to the TB treatment guidelines using the standard four-
combined regimen (i.e., isoniazid, rifampicin, ethambutol, and
pyrazinamide in the first two months, followed by isoniazid,
rifampicin with or without ethambutol) in 71.3% of TB cases.
Another 8.2% received the three-combined regimen (i.e., iso-
niazid, rifampicin plus ethambutol).
Within the first two months of anti-TB treatment, the number
of days receiving isoniazid had good correlation with the number
of days receiving rifampin, pyrazinamide, $3 drugs, #1 drug, and
without treatment (Kendall correlation coefficient: 0.344, 0.375,
0.573, 20.586, and 20.442, respectively). Compared to TB
patients who did not develop COPD, those who developed COPD
were older and were more likely to be male, and receive anti-TB
treatment later with more interruption or modification in regimen.
Kaplan-Meier analysis showed that a longer delay in anti-TB
treatment was significantly associated with the development of
COPD (Fig. 4).
Cox proportional hazards regression analysis was performed for
the 3,176 pulmonary TB subjects to identify independent risk
factors for developing COPD and showed that delay in anti-TB
treatment was an independent risk factor (HR 1.005 [range,
1.003–1.007]) (Table 5). Age and male sex were risk factors for
Table 1. Clinical characteristics of subjects at the initial study date.
Tuberculosis, n=3176 Control, n=15880 p value
Age (year) 51.9619.2 51.9619.2 0.999
Male 2080 (65.5) 10400 (65.5) 1.000
Developing COPD 241 (7.6) 624 (3.9) ,0.001
Follow up duration (year) 4.462.3 4.562.2 0.005
in those developing COPD 2.361.4 2.561.3 0.050
in those not developing COPD 4.662.2 4.662.2 0.496
Cancelled health insurance 16 (0.5) 60 (0.4) 0.304
Diabetes mellitus 569 (17.9) 1292 (8.1) ,0.001
Malignancy 89 (2.8) 305 (1.9) 0.001
lung cancer 3 (0.1) 7 (0.0) 0.225
other cancer 86 (2.7) 298 (1.9) 0.002
End-stage renal disease 36 (1.1) 60 (0.4) ,0.001
Autoimmune disease 17 (0.5) 31 (0.2) ,0.001
Liver cirrhosis 6 (0.2) 13 (0.1) 0.114
Acquired immuno-deficiency syndrome 6 (0.2) 3 (0.0) 0.001
Organ transplantation 1 (0.0) 7 (0.0) 1.000
Low income 87 (2.7) 186 (1.2) ,0.001
Ever undergoing spirometry 103 (3.2) 381 (2.4) 0.006
Abbreviation: COPD, chronic obstructive pulmonary disease.
Data were either number (%) or mean 6 SD.
doi:10.1371/journal.pone.0037978.t001
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the sensitivity analysis of females only, delay in anti-TB treatment
remained an independent risk factor and the magnitude of
association was slightly higher (HR 1.009 [range, 1.004–1.013]).
However, diabetes mellitus was not protective in the female sub-
population.
Discussion
Using a national insurance database, the present study has two
main findings. First, aside from the well-known predisposing
factors of COPD like age, male sex, and low income, history of
tuberculosis is an independent risk factor for developing COPD
and its impact is sustained for at least six years after TB diagnosis.
Second, among TB patients, delay in anti-TB treatment has a dose-
response relationship with the risk of developing COPD. These
findings have important clinical impact for the management of TB
and COPD, suggesting that some COPD cases may be prevent-
able by controlling the TB epidemic and improving the quality of
TB diagnosis and treatment. Moreover, follow-up care and early
intervention for COPD may be necessary for TB patients after
anti-TB treatment.
Tuberculosis is characterized of chronic caseous granulomatous
inflammation resulting in devastating tissue damage if left
untreated [18]. As the most common site of involvement,
pulmonary TB can cause permanent obstructive or restrictive
pulmonary function impairment, which in turn can contribute to
the pathogenesis of COPD [11–13]. In a nationwide survey in
South Africa, the strongest predictor of COPD is a history of
pulmonary TB, with odds ratio (OR) of 4.9 (95% CI 2.6–9.20) for
males and 6.6 (95% CI 3.7–11.9) for females [6]. The study is,
however, limited by the use of self-reported symptoms to define
COPD.
By using post-bronchodilator pulmonary function (FEV1/
FVC,0.70) to define COPD, subsequent case control studies
supported the possible contribution of prior pulmonary TB history
Figure 2. Prescription of antitussives, chronic obstructive
pulmonary disease (COPD)-specific medication, and spirome-
try in tuberculosis patients and control subjects. Prescription
data aggregated every 6 months from the individual initial study date
and presented as mean (circle) and 95% confidence interval (error bar).
doi:10.1371/journal.pone.0037978.g002
Figure 3. Curves of time to onset of chronic obstructive
pulmonary disease (COPD) among tuberculosis and control
groups.
doi:10.1371/journal.pone.0037978.g003
Table 2. Independent risk factors for developing COPD in
pulmonary tuberculosis patients (n=3176) and control
subjects (n=15880), by Cox proportional hazards regression
analysis.
p value Hazard ratio (95% CI)
Age ,0.001 1.047 (1.043–1.052)
Male ,0.001 2.001 (1.687–2.373)
Tuberculosis ,0.001 2.054 (1.768–2.387)
Diabetes mellitus 0.003 0.730 (0.591–0.902)
Low income 0.048 1.549 (1.004–2.390)
doi:10.1371/journal.pone.0037978.t002
Pulmonary TB-Induced COPD
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according to history and questionnaire only. The current analyses
complement these reports by demonstrating the temporal associ-
ation of TB preceding COPD at the population level using
prospectively collected data. It is likely that the absolute effect is
somewhat underestimated by the relatively insensitive definition of
COPD. A previous study in patients with drug-susceptible
pulmonary TB found that anti-tuberculous treatment can result in
minimal structural and functional residua [20]. Consistently, the
current findings suggest that a delay in initiating anti-TB
treatment may further aggravate airway destruction and accelerate
the development of COPD.
Table 3. Impact of pulmonary TB on developing COPD in
sensitivity analyses.
Study population p value Hazard ratio (95% CI)
All subjects ,0.001 2.054 (1.768–2.387)
Cases of follow-up duration .2 years ,0.001 1.565 (1.249–1.960)
Cases of follow-up duration .3 years 0.003 1.577 (1.163–2.139)
Cases of follow-up duration .4 years 0.008 1.780 (1.160–2.731)
Cases of follow-up duration .5 years ,0.001 3.641 (2.024–6.550)
Cases of follow-up duration .6 years 0.008 3.361 (1.372–8.239)
Age #40 years ,0.001 4.291 (2.623–7.020)
Age .40 years ,0.001 1.937 (1.653–2.269)
Age .50 years ,0.001 1.836 (1.553–2.169)
Age .60 years ,0.001 1.684 (1.400–2.026)
Age .70 years ,0.001 1.607 (1.261–2.049)
Women ,0.001 2.473 (1.782–3.433)
Men ,0.001 1.975 (1.669–2.337)
Abbreviations: COPD, chronic obstructive pulmonary disease; TB, tuberculosis.
doi:10.1371/journal.pone.0037978.t003
Table 4. Clinical characteristics at the initial study date of tuberculosis cases (n=3176) with or without subsequent chronic
obstructive pulmonary disease.
Developing COPD, n=241 Not developing COPD, n=2935 p value
Age (year): mean 62.5614.9 51.1619.2 ,0.001
Male 188 (78.0) 1892 (64.5) ,0.001
Diabetes mellitus 36 (14.9) 533 (18.2) 0.210
Malignancy 8 (3.3) 81 (2.8) 0.613
End-stage renal disease 0 (0.0) 36 (1.2) 0.108
Autoimmune disease 0 (0.0) 17 (0.6) 0.634
Liver cirrhosis 0 (0.0) 6 (0.2) 1.000
AIDS 0 (0.0) 6 (0.2) 1.000
Organ transplantation 0 (0.0) 1 (0.0) 1.000
Low income 9 (3.7) 78 (2.7) 0.325
Delay in ATT (days) 94.9664.8 74.3665.2 ,0.001
No. of days in first 2 months of ATT
receiving isoniazid 43.7621.2 46.2619.5 0.082
receiving rifampicin 48.2613.0 49.9612.0 0.041
receiving ethambutol 49.7613.3 48.7613.8 0.323
receiving pyrazinamide 45.0621.2 48.1619.8 0.031
without ATT 3.468.0 2.566.6 0.079
receiving #1 drug 6.069.7 5.269.0 0.194
receiving $3 drugs 47.7613.1 49.4612.4 0.044
Abbreviations: AIDS, acquired immuno-deficiency syndrome; ATT, anti-tuberculous treatment; COPD, chronic obstructive pulmonary disease.
Data were either number (%) or mean 6 SD.
doi:10.1371/journal.pone.0037978.t004
Figure 4. Curves of time to onset of chronic obstructive
pulmonary disease (COPD) among TB patients with different
delays in anti-tuberculous treatment.
doi:10.1371/journal.pone.0037978.g004
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specific, and easily attributed to other common clinical illness.
Delay in initiation of treatment is appreciable for patients with
either smear-positive or smear-negative pulmonary TB [21]. In
addition to increasing the severity of TB and further transmission,
delays in diagnosis and treatment may have long-term pulmonary
sequelae and render the development of COPD. With the
implementation of liquid mycobacterial culture system, the
diagnosis of pulmonary TB for smear-negative disease still requires
two weeks or more [22]. A high index of clinical suspicion and
prompt mycobacteriologic studies, including acid-fast smears,
mycobacterial culture, and even rapid molecular diagnostic test,
are of practical importance for both TB and COPD.
Tobacco smoking is the most important risk factor for COPD
[1]. It also increases susceptibility to TB and is associated with TB
treatment failure [1,17,23]. Since a history of smoking and other
environmental factors (e.g., biomass fuel exposure) are not
available in the LHID 2005, it is possible that some of the effects
of pulmonary TB on the development of COPD observed in
present study are through the effect of toxic substances. In
a previous report on COPD prevalence in 12 Asia-Pacific
countries and regions [24], smoking and air pollution, rather than
biomass fuel, were the most important risk factors of COPD in
Taiwan. Men were more likely to have the two kinds of exposure
than women. Results of sensitivity analysis in the present study that
included females only reveals that even in this predominantly non-
smoking population, previous TB and delay in anti-TB treatment
are still independent risk factors for COPD. Though the sensitivity
analysis cannot dissect the influences of these confounding factors,
the current findings suggest that TB maybe a risk factor of COPD
itself or a surrogate of inhalation of toxic substances and low socio-
economic status.
In addition, Lee et al. recently demonstrated that prior history
of TB was independently associated with airflow obstruction after
adjusting for age, sex, and smoking status [25]. Radiologic severity
of prior TB was also associated with the severity of non-smoker
COPD [25]. All of these evidences emphasize that clinicians
should keep a high index of suspicion for COPD in patients with
prior TB history.
Another finding in the present study is that diabetes mellitus
may have a protective effect on the development of COPD. This is
probably because patients may stop smoking after diabetes mellitus
is diagnosed, since the protective effect disappears when the
analysis is restricted to the predominantly non-smoking female
sub-population. The typical histologic finding of TB is caseous
granulomatous inflammation, in which matrix metalloproteinases
(MMPs) produced by monocytes and neutrophils are recently
identified as key mediators for the matrix destruction [26]. The
MMPs have also been shown to mediate the pathogenesis of
COPD and predict its pulmonary function decline [27]. Mean-
while, diabetes mellitus is associated with monocyte and neutrophil
dysfunction with impaired phagocytosis and migration [28,29].
Although the finding has not yet been confirmed, it is possible that
such immune cell dysfunction may modify matrix destruction and
reduce the risk of developing COPD.
The present study has some limitations. First, mycobacteriologic
results, pulmonary function test, and radiological findings were not
available. Therefore, it is difficult to confirm the diagnosis of
pulmonary TB and COPD. Other respiratory diseases, especially
asthma, may be misclassified as COPD. However, the analysis
reveals that pulmonary TB remains an independent risk factor
even in subjects aged .70 years, a population that is more likely to
have COPD rather than asthma. The conclusions here may be
applied to the management of TB and COPD since the findings
have been generated from the national insurance database,
a record of medical practice in the real world.
Second, the prevalence of COPD may be underestimated,
especially in the control subjects, because pulmonary function tests
are less frequently prescribed in control subjects. However, in
addition to spirometry, TB patients have more prescriptions of
antitussives and COPD-specific medication than control subjects
after the initial study date, suggesting that respiratory symptoms,
a key feature of COPD, are more common during post-TB follow-
up. Furthermore, the possibility of undiagnosed COPD prior to
the initial study date may also still exist, despite an observation
period of three years. Thus, the impact of TB increases as follow-
up duration increased.
Third, without knowing the clinical reasons for the timing of
treatment with specific anti-TB drugs, calculation of treatment
delay is somewhat arbitrary and its impact on the development of
COPD are probably less secure. Clinical studies with longer
follow-up duration are warranted to fully understand the in-
teraction between TB and COPD.
In conclusion, pulmonary tuberculosis is an independent and
long-lasting risk factor for developing COPD. Any delay in
initiating anti-TB treatment remains a serious issue and increases
the risk of COPD. In order to control TB epidemics and reduce
COPD burden, early diagnosis of pulmonary TB and prompt
initiation of appropriate anti-TB treatment is imperative. Further
studies on the post-treatment course of pulmonary TB are needed
to optimize follow-up care and early intervention for COPD.
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